News from i-mab biopharma A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Nov 02, 2018, 09:06 ET I-Mab and Genexine Announce China IND Approval for Innovative Immunotherapy

I-MAB Biopharma Co., Ltd. ("I-Mab"), a Shanghai-based biotech company exclusively focused on innovative biologics in immuno-oncology and autoimmune...


Oct 12, 2018, 02:01 ET First Patient Dosing achieved in Mainland China in a Phase II Multi-regional clinical trial (MRCT)

I-Mab Biopharma ("I-Mab"), a company focusing on innovative biologics in immuno-oncology and immuno-inflammation, today announced that the first...


Sep 26, 2018, 09:23 ET I-Mab Biopharma Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody™ Platform for Three Bispecific Antibody Programs

WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery,...


Sep 19, 2018, 03:33 ET I-Mab Wins Frost & Sullivan "2018 Best R&D Innovator Award (Biopharma Category)"

I-Mab Biopharma ("I-Mab") announced today that it has been recognized by Forest & Sullivan, the global leading growth consulting company as well as...


Aug 09, 2018, 04:16 ET I-Mab's Announces China Clinical Trial Approval of Long-acting hGLP-1 to Treat Type 2 Diabetes

In July, 2018, I-Mab Biopharma (I-Mab) announced that it received clinical trial approval from China National Drug Administration (CNDA) for TJ103...


Aug 07, 2018, 21:01 ET I-Mab Biopharma and MorphoSys Announce China IND Submission of TJ202/MOR202

On August 8, 2018 Beijing time I-Mab Biopharma ("I-Mab"), a Shanghai-based biotech company focused on innovative biologics in oncology and autoimmune ...


Jul 31, 2018, 20:44 ET I-Mab Biopharma Announces New CFO

On August 1, 2018 Beijing time, I-Mab Biopharma ("I-Mab"), a Shanghai-based biotech company focused on innovative biologics in oncology and...


Jul 26, 2018, 09:30 ET I-Mab Biopharma and ABL Bio Announce Global Collaboration on Innovative Bispecific Antibodies

I-Mab Biopharma ("I-Mab"), a company focusing on innovative biologics in immuno-oncology and immuno-inflammation, and ABL Bio Corporation ("ABL...


Jun 29, 2018, 05:42 ET I-Mab Successfully Raised USD 220 Million in Series C Funding

I-Mab Biopharma, a company focusing on innovative Biologics in therapeutic areas of immuno-oncology and immuno-inflammation, announced the completion ...


Dec 25, 2017, 05:50 ET I-Mab Biopharma Signs Licensing Agreement for HyLeukin With Genexine

- Genexine to receive an upfront payment and entitled to tiered, single-digit royalties on net sales of HyLeukin plus milestone payments from I-Mab...


Dec 01, 2017, 01:55 ET I-Mab Biopharma Partners with MorphoSys on Cancer Investigational Medicine

I-Mab Biopharma (I-Mab) and MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) announced today that they have entered into an...